MedTrace Logo

Tafluprost Preservative Free Switch Study

NCT04654611 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2020-12-04

No results posted yet for this study

Summary

This study is conducted to document the effect of switching from preserved prostaglandin analogues monotherapy to preservative free tafluprost 0.0015%. The endpoints analyzed are side effect improvement in these patients.

Conditions

Interventions

DRUG

preservative free tafluprost 0.0015%

preservative free prostaglandin analogue option for treatment of primary open angle glaucoma and ocular hypertension patients

Sponsors & Collaborators

  • Tun Hussein Onn National Eye Hospital

    lead OTHER

Principal Investigators

  • Hsien Han Lim · Tun Hussein Onn National Eye Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-02-01
Primary Completion
2020-02-01
Completion
2020-02-01

Countries

  • Malaysia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04654611 on ClinicalTrials.gov